MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback